HBM Holdings(02142.HK): Strategic Cooperation Established with Sinopharm Group

NewTimeSpace News: On July 27, 2026, HBM Holdings(02142.HK) issued an announcement stating that the Company has entered into a strategic cooperation agreement with Sinopharm Group. The two parties will set up an innovation consortium to carry out R&D collaboration covering the full life cycle of innovative biologic drugs, with strategic focus on therapeutic areas including oncology, immunity and inflammation.

Pursuant to the agreement, HBM Holdings will leverage its globally leading fully human antibody technology platform Harbour Mice® and AI-empowered R&D capabilities for the discovery and optimization of antibody candidate molecules, including target validation, lead antibody identification and optimization, antibody format design and antibody engineering. Sinopharm Group will contribute its expertise in clinical trials, large-scale manufacturing and commercialization, undertaking process development for commercial-scale production, clinical material manufacturing and product commercialization. The two parties will jointly bear R&D costs and share product rights and interests as agreed.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.